Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients

Genes

Giacomo Montagna¹  Carmen Criscitiello²  Maurizio Bruno Nava³  Nicola Rocco⁴  Antonio Gloria⁵  Francesca Privitera⁶  Giuseppe Catanuto⁶  Wafa Taher⁷ 

[1] Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10001, USA;Department of Oncology and Haematology (DIPO), University of Milan, 20122 Milan, Italy;G.RE.T.A. Group for Reconstructive and Therapeutic Advancements, 20122 Milan, Italy;G.RE.T.A. Group for Reconstructive and Therapeutic Advancements, 80100 Naples, Italy;Institute of Polymers, Composites and Biomaterials—National Research Council of Italy, 80125 Naples, Italy;Multidisciplinary Breast Unit, Azienda Ospedaliera Cannizzaro, 95021 Catania, Italy;Surrey and Sussex Health Care, NHS Trust, London W1W 5EF, UK;

关键词: breast cancer;    BRCA mutations;    risk reduction;    nipple-sparing mastectomies;   

DOI  :  10.3390/genes12020253

来源: DOAJ

【 摘 要 】

Growing numbers of asymptomatic women who become aware of carrying a breast cancer gene mutation (BRCA) mutation are choosing to undergo risk-reducing bilateral mastectomies with immediate breast reconstruction. We reviewed the literature with the aim of assessing the oncological safety of nipple-sparing mastectomy (NSM) as a risk-reduction procedure in BRCA-mutated patients. Nine studies reporting on the incidence of primary breast cancer post NSM in asymptomatic BRCA mutated patients undergoing risk-reducing bilateral procedures met the inclusion criteria. NSM appears to be a safe option for BRCA mutation carriers from an oncological point of view, with low reported rates of new breast cancers, low rates of postoperative complications, and high levels of satisfaction and postoperative quality of life. However, larger multi-institutional studies with longer follow-up are needed to establish this procedure as the best surgical option in this setting.

【 授权许可】

Unknown